09.05.26 -- Drug Delivery Leader Best Of August

Watch Drug Delivery Leader Live on 9/17/26 to explore how digitally connected autoinjectors, wearable injectors, and other self-administered drug delivery technologies are transforming patient care. Industry experts will discuss digital monitoring, adherence, dosing accuracy, regulatory expectations, and product development strategies that improve outcomes while supporting decentralized care. Discover the technical, business, and regulatory considerations shaping the future of connected drug delivery. Register free today!

In this episode of In Combination, Paul Chao and Carolyn Dorgan from combination product and delivery device consultancy Suttons Creek join host Tom von Gunden to discuss strategic considerations and best practices for employing technology platforms in device development for injection-based delivery. The conversation illuminates aspects such as the design space across product assets in development, component options within a platform offering, and regulatory pathways for platform-based submissions. 

In this article, Fran DeGrazio discusses the opportunities, challenges, and benefits for biopharmaceutical product developers in transitioning from vial-based to prefilled syringe (PFS) delivery approaches. She lays out key differences and added complexities in areas such as device functionality, risk management, regulatory pathways, use of materials, lifecycle management, and organizational alignment.

In this article, Chief Editor Tom von Gunden considers the expanding range of addressable targets for inhalation drug and biologics delivery. He reports on innovations in oral and nasal inhalation technology that enhance approaches to traditional respiratory indications, as well enable delivery of inhaled therapies to systemic targets beyond the nose and lungs.

This disposable pen for Semaglutide is a generic drug-device combination, designed for usability and regulatory compliance, showing comparable performance to the reference device.

A sprinkle formulation helps patients with tremors or dysphagia take medication more easily, improving adherence, comfort, and care through a novel, FDA-approved oral granule format.

Advances in sustained-release drug delivery could improve efficiency and consistency in drug release, manifesting real-life advantages for patients in the form of enhanced accessibility and compliance.